(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The many ways that baking is winter therapy. With a delicious ending - 2Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- 3The 1st full moon of 2026 rises tonight! Here's what to expect from January's supermoon Wolf Moon
- 4Smooth countdown continues for Artemis II moon mission
- 5Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
- Vote In favor of Your Favored Web based Dating Application
- ‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- Sports Shoes of 2024: Upgrade Execution and Solace
- Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- Share your pick for the tree that you love for its novel magnificence!
- 10 Energizing Vocations in the Innovation Business
- Israel says 40 Hezbollah members killed as forces advance in Lebanon
- Watch SpaceX launch 119 payloads to orbit from California early on March 30
